Patents Assigned to Rush University Medical Center
-
Patent number: 8889166Abstract: A plastic implant device for a mammal that contains a rare earth metal compound tracer and a method for detecting degradation such as wear of the implanted device are disclosed. The tracer can also be present with a separate antioxidant or the tracer compound can be can be the salt of a C6-C22 unsaturated carboxylic acid. The rare earth metal compound tracer is released when the prosthetic is worn down or otherwise degraded in the mammalian body in which it was implanted. The presence and amount of released tracer present in a body fluid or tissue sample measured and is proportional to the degree of degradation of the implant.Type: GrantFiled: July 29, 2009Date of Patent: November 18, 2014Assignee: Rush University Medical CenterInventors: Achim Kunze, Markus Wimmer, Joshua J. Jacobs
-
Patent number: 8889167Abstract: A plastic implant device for a mammal that contains a rare earth metal compound tracer and a method for detecting degradation such as wear of the implanted device are disclosed. The tracer can also be present with a separate antioxidant or the tracer compound can be can be the salt of a C6-C22 unsaturated carboxylic acid. The rare earth metal compound tracer is released when the prosthetic is worn down or otherwise degraded in the mammalian body in which it was implanted. The presence and amount of released tracer present in a body fluid or tissue sample measured and is proportional to the degree of degradation of the implant.Type: GrantFiled: October 9, 2009Date of Patent: November 18, 2014Assignee: Rush University Medical CenterInventors: Achim Kunze, Markus Wimmer, Joshua J. Jacobs
-
Publication number: 20140314710Abstract: A novel approach to discover new drugs against MS and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (IL-12), the p40 monomer (p40), the p40 homodimer (p402), and the IL-23. To facilitate the studies on p402 and p40, neutralizing monoclonal antibodies (mAb) against mouse p402 and p40 were generated for the first time. MS and other autoimmune disease drug therapies including recombinant p40 and/or monoclonal antibody against p402 (mAb-p402 a3-1d) are disclosed.Type: ApplicationFiled: May 21, 2012Publication date: October 23, 2014Applicant: RUSH UNIVERSITY MEDICAL CENTERInventor: Kalipada Pahan
-
Publication number: 20140309715Abstract: An energy-releasing carbon nanotube transponder comprising a nanocapacitor connected to at least one carbon nanotube and method of using same are described. An adjustable amount of electric energy is stored within the nanocapacitor so that the energy-releasing carbon nanotube transponder delivers either a biologically destructive or a biologically non-destructive electrical charge to target cells in response to biological, chemical or electrical stimuli. An optional biocompatible coating onto the outer surface of the carbon nanotube transponder improves cellular targeting, cellular binding or body tolerance towards the carbon nanotube transponder. Optionally, a molecular label attached to at least one carbon nanotube allows for in vivo tracking of the carbon nanotube transponder.Type: ApplicationFiled: June 27, 2014Publication date: October 16, 2014Applicant: Rush University Medical CenterInventor: Marvin A. Rossi
-
Publication number: 20140274772Abstract: A method and a kit for assessing risk of lung cancer versus benign disease in a subject are provided. The method includes obtaining a biological sample from the subject and determining a measurement for a panel of biomarkers in the biological sample. The panel includes at least two biomarkers selected from the group consisting of IL-6, IL-1ra, IL-10, SDF-1?+?, TNF-?, MIP-1?, sIL-2R?, CA-125, sE-Selectin, Eotaxin, sEGFR, MMP-2, OPN, MCP-1, CRP, sICAM-1 and CYFRA 21.1. The method further includes comparing the measurement to a reference profile for the panel of biomarkers, sorting the subject into a group and determining whether the subject is at risk for lung cancer based on the group.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Rush University Medical CenterInventors: Jeffrey A. BORGIA, Michael LIPTAY
-
Patent number: 8788033Abstract: An energy-releasing carbon nanotube transponder comprising a nanocapacitor connected to at least one carbon nanotube and method of using same are described. An adjustable amount of electric energy is stored within the nanocapacitor so that the energy-releasing carbon nanotube transponder delivers either a biologically destructive or a biologically non-destructive electrical charge to target cells in response to biological, chemical or electrical stimuli. An optional biocompatible coating onto the outer surface of the carbon nanotube transponder improves cellular targeting, cellular binding or body tolerance towards the carbon nanotube transponder. Optionally, a molecular label attached to at least one carbon nanotube allows for in vivo tracking of the carbon nanotube transponder.Type: GrantFiled: March 15, 2012Date of Patent: July 22, 2014Assignee: Rush University Medical CenterInventor: Marvin A. Rossi
-
Publication number: 20140179629Abstract: Compositions which provide slowly digestible starch and a source of fermentable dietary fiber. Microparticles in which starch is entrapped in a crosslinked matrix to provide dietary benefit. Such microparticles are used to deliver glucose to targeted regions in the small intestine for beneficial physiological effects, and fermentable dietary fiber to the colon to improve colon health and to treat diseases of the colon. Microparticles can be employed to selectively deliver fermentable dietary fiber to targeted portions of the colon.Type: ApplicationFiled: October 14, 2013Publication date: June 26, 2014Applicants: RUSH UNIVERSITY MEDICAL CENTER, PURDUE RESEARCH FOUNDATIONInventors: BRUCE R. HAMAKER, MAHESH VENKATACHALAM, GENYI ZHANG, ALI KESHAVARZIAN, DEVIN J. ROSE
-
Patent number: 8747310Abstract: The invention covers a method and apparatus for assessing the health of an infant by accurately estimating the average growth velocity of the infant. The invention employs an exponential model to estimate growth velocity based on at least two weight measurements from different days of life of an infant. The exponential model provides the accuracy and ease of use that are lacking in current methods applied to growth research. The exponential model has numerous features that make it a desirable and powerful model, i.e., (1) it is extremely accurate; (2) it is simple to use, requiring only weight and day of life at 2 time points; (3) it is robust under various testing conditions; and (4) it is unaffected by clinical factors found commonly among ELBW infants, which allows its broad application for the study of infant growth. The exponential model closely approximates the accurate standard GVs, regardless of starting point or time interval used.Type: GrantFiled: November 27, 2006Date of Patent: June 10, 2014Assignee: Rush University Medical CenterInventor: Robert E. Kimura
-
Publication number: 20140148891Abstract: A bifurcated catheter, which can deploy a bifurcated stent constructed as a single piece into a bifurcated vessel, is disclosed. The system may have two main parts—a y-shaped catheter with a splittable seam, and a custom made stent, which can be deployed with the bifurcated catheter. The disclosed bifurcated catheter permits a physician or operator to stent a vessel at a bifurcation of the vessel.Type: ApplicationFiled: July 12, 2012Publication date: May 29, 2014Applicant: RUSH UNIVERSITY MEDICAL CENTERInventor: Andrew K. Johnson
-
Publication number: 20140147856Abstract: A method of identifying a subject at risk of developing or having a neurodegenerative disorder is provided. The method includes obtaining a biological sample from the subject and assaying a level of a marker of intestinal permeability in the sample. The method further includes comparing the subject's level to a control level for the marker of intestinal integrity and identifying the subject having an increased intestinal permeability relative to the control intestinal permeability as having an increased risk of developing or having a neurodegenerative disorder. A method of monitoring the efficacy of a treatment for a neurodegenerative disorder is also provided.Type: ApplicationFiled: November 25, 2013Publication date: May 29, 2014Applicant: Rush University Medical CenterInventors: Christopher Forsyth, Maliha Shaikh, Kathleen Shannon, Jeffrey Kordower, Ali Keshavarzian, David A. Bennett
-
Patent number: 8722351Abstract: Methods and compositions, and a kit for diagnosing ovarian disorders including autoimmunity and ovarian cancer. Ovarian autoimmunity is associated with unexplained infertility or idiopathic premature ovarian failure that occurs in the absence of polyglandular disease. Methods and composition described herein are used to detect ovarian autoimmunity before the onset of ovarian dysfunction. Thus, those individuals are identified who would benefit from therapy to maintain, as well as restore, ovarian function.Type: GrantFiled: September 17, 2010Date of Patent: May 13, 2014Assignee: Rush University Medical CenterInventors: Judith Luborsky, Seby Edassery
-
Publication number: 20140121235Abstract: Disclosed herein are methods for treating an S6K-overexpressing cancer, comprising administering a therapeutically effective amount of leflunomide to a subject in need thereof.Type: ApplicationFiled: October 25, 2013Publication date: May 1, 2014Applicant: Rush University Medical CenterInventor: Xiulong Xu
-
Publication number: 20140107626Abstract: A kit and/or method for use during surgery is configured to decrease the risk of accidental retention of foreign objects, such as surgical items or medical devices, used in surgery inside of a patient after the surgery is completed. Specifically, illustrative kits may include, but not be limited to, a combination of one or more foreign objects, an anchoring member attached to a point outside of the patient or surgical field, and at least one or more connection members connecting the foreign objects to the anchoring member. Illustrative methods may include, but not be limited to, anchoring one or more foreign object by one or more connection members, wherein a first end of each connection member is attached to the foreign object, and a second end of each connection member is attached to a junction member; attaching the junction member to an anchoring member; and attaching the anchoring member to a structure that is outside the patient or surgical field.Type: ApplicationFiled: September 26, 2013Publication date: April 17, 2014Applicant: RUSH UNIVERSITY MEDICAL CENTERInventor: Richard W. BYRNE
-
Publication number: 20140038223Abstract: This disclosure identifies a novel apoptotic compensatory proliferation signaling complex (ASCS) involving ExoT's cellular target, Crk1. This disclosure demonstrates that in cells induced to undergo apoptosis, Crk1 forms globular complexes which associate with plasma membrane in the apoptotic cell and are released from the dying cell to its healthy neighbor, inducing it to proliferate. ExoT prevents the ACSC assembly while inducing apoptosis, indicating that apoptotic program cell death and compensatory proliferation are distinct and can be uncoupled from each other. Without being bound to any particular theory, it is believed that Crk1 functions as a scaffold for the ACSC assembly and that its ADP-ribosylation by ExoT interferes with this process while resulting in anoikis apoptotic cell death.Type: ApplicationFiled: March 30, 2012Publication date: February 6, 2014Applicant: Rush University Medical CenterInventor: Sasha Shafikhani
-
Publication number: 20130331436Abstract: Methods and compositions are disclosed to identify plasma and vitreous microRNA (miRNA) signatures of diabetic retinopathy (DR), and then as diagnostic biomarkers for the onset and progression of DR.Type: ApplicationFiled: May 31, 2013Publication date: December 12, 2013Applicant: RUSH UNIVERSITY MEDICAL CENTERInventor: Shunbin Xu
-
Patent number: 8557274Abstract: Compositions which provide slowly digestible starch and a source of fermentable dietary fiber. Microparticles in which starch is entrapped in a crosslinked matrix to provide dietary benefit. Such microparticles are used to deliver glucose to targeted regions in the small intestine for beneficial physiological effects, and fermentable dietary fiber to the colon to improve colon health and to treat diseases of the colon. Microparticles can be employed to selectively deliver fermentable dietary fiber to targeted portions of the colon. A method for making the microparticles is provided as well as methods for using the microparticles for controlled digestion of starch on ingestion in the small intestine and methods for using the microparticles to deliver dietary fiber. The microparticles with entrapped starch provide a low glycemic index and extended glucose release in food products and food ingredients.Type: GrantFiled: December 6, 2006Date of Patent: October 15, 2013Assignees: Purdue Research Foundation, Rush University Medical CenterInventors: Bruce R. Hamaker, Mahesh Venktachalam, Genyi Zhang, Ali Keshavarzian, Devin J. Rose
-
Publication number: 20130225442Abstract: Methods for the diagnosis of lung cancer and more specifically, non-small cell lung cancer are described. An assortment of biomarkers with diagnostic or prognostic value for non-small cell lung cancer (NSCLC) are used to establish a multi-analyte serum test capable of diagnosing patients with lung cancer. A first method assesses an elevated level of expression of one or more nucleic acids, a polypeptide encoded by the nucleic acid or an autoantibody to said polypeptide. An alternative method includes (a) determining whether or not a patient has NSCLC versus a non-NSCLC lung cancer, and (b) classifying the patient as susceptible to specific treatments if the patient has a NSCLC profile and classifying the patient as not susceptible to a specific treatment if the patient does not have a NSCLC profile.Type: ApplicationFiled: October 20, 2011Publication date: August 29, 2013Applicant: RUSH UNIVERSITY MEDICAL CENTERInventor: Jeffrey A. Borgia
-
Patent number: 8497066Abstract: A DNA methylation-based test for efficiency of treatments is based on a plurality of genes. The test is suitable for monitoring treatment of subjects with neurological diseases, e.g., multiple sclerosis (MS); with cancer, e.g., breast and ovarian cancer, and with other diseases for which methylation of biomarkers differs in the diseased compared to the non-diseased state.Type: GrantFiled: December 4, 2009Date of Patent: July 30, 2013Assignee: Rush University Medical CenterInventors: Victor Levenson, Anatoliy Melnikov, Roumen Balabanov, Dusan Stefoski
-
Publication number: 20130178442Abstract: Associations between inflammation and pain/function scores were tested by univariate and multivariate analyses. Gene expression was analyzed by microarray and real-time PCR comparing patients with and without synovial inflammation. Synovitis was present in 43% of patients presenting for arthroscopic menisectomy. Inflammation was associated with pre-operative Lysholm scores, independent of age, gender, and BMI. Synovial RNA microarray analysis revealed 260 genes differently expressed ?2-fold between patients with and without synovitis. A chemokine signature identified in the “inflammatory” biopsies was confirmed by real-time PCR. In conclusion, in patients presenting for arthroscopic menisectomy, synovitis is associated with symptoms. Comparison of expression patterns revealed enrichment of chemokines associated with cellular recruitment and activation in patients with synovitis.Type: ApplicationFiled: March 8, 2013Publication date: July 11, 2013Applicant: RUSH UNIVERSITY MEDICAL CENTERInventor: RUSH UNIVERSITY MEDICAL CENTER
-
Patent number: 8422820Abstract: Methods for identifying and quantifying recurrent and deterministic patterns in digital images are provided. The methods, which are based on Recurrence Quantification Analysis (RQA), generate similarity or dissimilarity distance matrices for digital images that may be used to calculate a variety of quantitative characteristics for the images. Also provided are methods for identifying and imaging spatial distributions of time variable signals generated from dynamic systems. In these methods a time variable signal is recorded for a plurality of area or volume elements into which a dynamic system has been sectioned and RQA is used to calculate one or more RQA variables for each of the area or volume elements, which may then be used to generate a two or three dimensional image displaying the spatial distribution of the RQA variables across the system.Type: GrantFiled: September 3, 2008Date of Patent: April 16, 2013Assignee: Rush University Medical CenterInventors: Joseph P. Zbilut, Paolo Sirabella, Marta Bianciardi, Alfredo Colosimo, Gisela Hagberg, Alessandro Giuliani